Kwality Pharmaceuticals LtdNSE: KPL

KPL: FY26 saw record revenue, margin expansion, and robust profit growth, with strong FY27 guidance

· Issued by Kwality Pharmaceuticals Ltd

Record FY26 revenue and profit growth driven by margin expansion, global market gains, and operational discipline. Guidance for FY27 targets ₹650 crore revenue and ₹100 crore PAT, with strong pipeline and capacity investments supporting future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis